It is essential to consult a healthcare provider for professional support
Weight loss is a primary driver of downstream hormonal benefits, with semaglutide producing up to 15% body weight reduction over 68 weeks and a 2025 trial reporting a mean loss of 5.6 kg, compared with 2.3 kg with other treatments
However, participants who had a history of, or met criteria for, conduct disorder, bipolar disorder, mania, or schizophrenia were excluded
Alcohol: Avoid alcohol on DSIP dosing nights
[7] [8] Ipamorelin has been used by athletes as a performance-enhancing drug
United States Department of Health and Human Services, United States Food and Drug Administration, Center for Drug Evaluation and Research & Center for Biologics Evaluation and Research